Differential adhesion-inhibitory patterns of antibodies raised against two major variants of the NTS-DBL2X region of VAR2CSA

Justin Doritchamou; Pascal Bigey; Morten Agertoug Nielsen; Sédami Gnidehou; Sem Ezinmegnon; Aurore Burgain; Achille Massougbodji; Philippe Deloron; Ali Salanti; Nicaise Tuikue Ndam

doi:10.1016/j.vaccine.2013.07.072

Differential adhesion-inhibitory patterns of antibodies raised against two major variants of the NTS-DBL2X region of VAR2CSA

Justin Doritchamou, Pascal Bigey, Morten Agertoug Nielsen, Sédami Gnidehou, Sem Ezinmegnon, Aurore Burgain, Achille Massougbodji, Philippe Deloron, Ali Salanti, Nicaise Tuikue Ndam

21 Citations (Scopus)

Abstract

VAR2CSA is a large polymorphic Plasmodium falciparum protein expressed on infected erythrocytes (IE) that allows their binding in the placenta, thus precipitating placental malaria (PM). The N-terminal part of VAR2CSA that contains the binding site to placental chondroitin sulfate A (CSA) is currently recognized as the most attractive region for vaccine development. An ultimate challenge is to define epitopes in this region that induce a broad cross-reactive adhesion inhibitory antibody response.

Original language	English
Journal	Vaccine
Volume	31
Issue number	41
Pages (from-to)	4516-22
Number of pages	7
ISSN	0264-410X
DOIs	https://doi.org/10.1016/j.vaccine.2013.07.072
Publication status	Published - 23 Sept 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2013.07.072

Cite this

@article{8824816ef0914a889b0100029aea4493,

title = "Differential adhesion-inhibitory patterns of antibodies raised against two major variants of the NTS-DBL2X region of VAR2CSA",

abstract = "VAR2CSA is a large polymorphic Plasmodium falciparum protein expressed on infected erythrocytes (IE) that allows their binding in the placenta, thus precipitating placental malaria (PM). The N-terminal part of VAR2CSA that contains the binding site to placental chondroitin sulfate A (CSA) is currently recognized as the most attractive region for vaccine development. An ultimate challenge is to define epitopes in this region that induce a broad cross-reactive adhesion inhibitory antibody response.",

author = "Justin Doritchamou and Pascal Bigey and Nielsen, {Morten Agertoug} and S{\'e}dami Gnidehou and Sem Ezinmegnon and Aurore Burgain and Achille Massougbodji and Philippe Deloron and Ali Salanti and Ndam, {Nicaise Tuikue}",

year = "2013",

month = sep,

day = "23",

doi = "10.1016/j.vaccine.2013.07.072",

language = "English",

volume = "31",

pages = "4516--22",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier",

number = "41",

}

TY - JOUR

T1 - Differential adhesion-inhibitory patterns of antibodies raised against two major variants of the NTS-DBL2X region of VAR2CSA

AU - Doritchamou, Justin

AU - Bigey, Pascal

AU - Nielsen, Morten Agertoug

AU - Gnidehou, Sédami

AU - Ezinmegnon, Sem

AU - Burgain, Aurore

AU - Massougbodji, Achille

AU - Deloron, Philippe

AU - Salanti, Ali

AU - Ndam, Nicaise Tuikue

PY - 2013/9/23

Y1 - 2013/9/23

N2 - VAR2CSA is a large polymorphic Plasmodium falciparum protein expressed on infected erythrocytes (IE) that allows their binding in the placenta, thus precipitating placental malaria (PM). The N-terminal part of VAR2CSA that contains the binding site to placental chondroitin sulfate A (CSA) is currently recognized as the most attractive region for vaccine development. An ultimate challenge is to define epitopes in this region that induce a broad cross-reactive adhesion inhibitory antibody response.

AB - VAR2CSA is a large polymorphic Plasmodium falciparum protein expressed on infected erythrocytes (IE) that allows their binding in the placenta, thus precipitating placental malaria (PM). The N-terminal part of VAR2CSA that contains the binding site to placental chondroitin sulfate A (CSA) is currently recognized as the most attractive region for vaccine development. An ultimate challenge is to define epitopes in this region that induce a broad cross-reactive adhesion inhibitory antibody response.

U2 - 10.1016/j.vaccine.2013.07.072

DO - 10.1016/j.vaccine.2013.07.072

M3 - Journal article

C2 - 23933341

SN - 0264-410X

VL - 31

SP - 4516

EP - 4522

JO - Vaccine

JF - Vaccine

IS - 41

ER -

Differential adhesion-inhibitory patterns of antibodies raised against two major variants of the NTS-DBL2X region of VAR2CSA

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this